# Varex Imaging Corporation (VREX) Investor Outlook: Analyzing a 56% Potential Upside for the Medical Device Maker

- Link: https://www.directorstalkinterviews.com/varex-imaging-corporation-vrex-investor-outlook-analyzing-a-56-potential-upside-for-the-medical-device-maker/4121249024
- Published: 2026-04-16T10:08:03+01:00
- Author: Madison Wilson

Varex Imaging Corporation (NASDAQ: VREX), a prominent player in the healthcare sector,
has piqued the interest of investors with its promising outlook and substantial 
potential upside. Despite navigating a challenging market environment, the company
is positioned within the medical devices industry, specializing in the design and
manufacture of X-ray imaging components. From its headquarters in Salt Lake City,
Utah, Varex extends its influence across multiple continents, including North America,
Europe, Asia, and beyond.

Varex’s current stock price stands at $11.78, hovering close to the midpoint of 
its 52-week range of $6.88 to $14.36. This valuation could be enticing for investors,
particularly given the stock’s potential upside of 56.20%, based on an average target
price of $18.40 from analysts. The optimistic sentiment is further underscored by
the fact that the company has received four buy ratings and only one hold, with 
no sell recommendations on record.

The financial health of Varex reflects both opportunities and challenges. Although
the company has reported a revenue growth of 4.90%, it faces headwinds with a negative
EPS of -1.64 and a return on equity of -12.90%. The negative free cash flow of approximately
$15.7 million and the absence of a dividend yield signal areas of concern that the
management will need to address to enhance shareholder value.

From a valuation standpoint, Varex’s forward P/E ratio of 11.18 suggests a reasonable
pricing relative to its earnings expectations, yet other valuation metrics such 
as the PEG ratio and Price/Book are currently unavailable, perhaps reflecting the
complexities in forecasting the company’s growth trajectory amid its current financial
performance.

Technical indicators offer additional insights into Varex’s stock movement. The 
RSI (Relative Strength Index) of 67.35 suggests that the stock is nearing overbought
conditions, while the MACD (Moving Average Convergence Divergence) and Signal Line
readings indicate a slightly bearish momentum. However, with the current price slightly
below the 50-day moving average of $12.10 and above the 200-day moving average of
$11.41, the stock maintains a balanced position that could shift positively with
market catalysts.

Varex Imaging’s business model is robust, catering to both medical and industrial
segments. In healthcare, its products are instrumental in critical diagnostic applications
such as CT scans and mammography, while its industrial offerings play a key role
in security and non-destructive testing. This dual-segment approach not only diversifies
revenue streams but also positions the company well to leverage growth in various
sectors.

As Varex Imaging continues to expand its footprint globally, investors should monitor
the company’s ability to convert its technological and market strengths into improved
financial metrics. The absence of dividends and current negative profitability metrics
are offset by the strategic importance of its products and potential for valuation
uplift.

For investors considering exposure to the medical devices sector, Varex presents
an intriguing case with substantial upside potential. The company’s global reach,
innovative product lines, and analyst endorsements underscore a promising future,
contingent on effective management of current financial challenges. As always, due
diligence and a keen eye on market developments will be crucial in navigating the
investment landscape surrounding Varex Imaging Corporation.

Share on: